Recent Financings Of Private Companies, October 2013
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Device, and Pharmaceuticals sector. This month’s column covers deals announced August through September 2013.
You may also be interested in...
Deals In Depth: August 2020
Biogen and Denali entered into a potential $2.15bn alliance for Denali’s DNL151 for Parkinson’s disease and other neurodegenerative diseases. Siemens Healthineers announced plans to acquire Varian Medical for $16.4bn. Financing reached $7.9bn in biopharma, $501m in device, and $639m in diagnostics.
Deals In Depth: July 2020
Daiichi Sankyo partnered its Phase I DS-1062 for non-small cell lung cancer and triple negative breast cancer with AstraZeneca in a deal that could be worth up to $6bn. Medtronic entered into an agreement to acquire Medicrea in an all-cash tender offer for total consideration of approximately $228m (including approximately $57M of net cash and liabilities). Financing reached $11.7bn in biopharma, $1.4bn in device, and $597m in diagnostics.
Dealmaking Quarterly Statistics, Q2 2020
During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.
Need a specific report? 1000+ reports available
Buy Reports